Comparative Pharmacology
Head-to-head clinical analysis: FALMINA versus LEVORA 0 15 30 28.
Peer-Reviewed Evidence
Head-to-head clinical analysis: FALMINA versus LEVORA 0 15 30 28.
FALMINA vs LEVORA 0.15/30-28
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Selective serotonin reuptake inhibitor (SSRI) that potentiates serotonergic activity in the CNS by inhibiting the reuptake of serotonin at the synaptic cleft, leading to increased serotonin levels.
Combination oral contraceptive containing ethinyl estradiol and levonorgestrel. Suppresses gonadotropin (FSH and LH) release from the pituitary, inhibiting ovulation. Also induces changes in cervical mucus (increasing viscosity) and endometrium (reducing receptivity) to impair sperm penetration and implantation.
FALMINA (fictitious drug): 500 mg orally every 12 hours.
One tablet orally once daily at the same time each day for 28 days (21 active tablets containing 0.15 mg levonorgestrel and 0.03 mg ethinyl estradiol, followed by 7 placebo tablets).
None Documented
None Documented
Terminal elimination half-life 12-15 hours; in severe renal impairment (CrCl <30 mL/min) extends to 30-40 hours, requiring dose adjustment.
Ethinyl estradiol: 13-27 hours (terminal); Levonorgestrel: 11-45 hours (terminal, dose-dependent due to SHBG binding).
Primarily renal (85% unchanged drug, 10% as glucuronide conjugate); biliary/fecal 5%.
Renal: ~50% (as glucuronide and sulfate conjugates of ethinyl estradiol and levonorgestrel); Fecal: ~50% (enterohepatic recirculation).
Category C
Category C
Oral Contraceptive
Oral Contraceptive